Pluristem appoints CEO, chairman

 

Pluristem Therapeutics Inc. has completed the transition period of its co-CEO structure and appointed Yaky Yanay as sole CEO and president of the company and Zami Aberman as executive chairman of the board.

“In the last 13 years, I proudly served Pluristem in different roles under Zami’s leadership,” Yanay says. “During these years, we were able to grow Pluristem from an early stage R&D company to a multi-Phase III studies company targeting major markets. Our PLX technology is a powerful technology that is aimed to save lives, increase quality of life and could have a major economic positive impact on the global healthcare system.

“I am honored with this appointment and I would like to thank Zami and the board of directors for their trust. My mission now is to lead Pluristem to become a large, successful, profitable company that will impact the medical world for the benefit of our patients, shareholders, employees and partners.”

Pluristem is developing novel placenta-based cell therapy product candidates. According to Aberman, the co-CEO structure has served Pluristem well over the past two years and allowed the company to implement the transition as seamlessly as possible.

“As executive chairman I will continue to take an active role in shaping Pluristem’s corporate development and business strategy as we are advancing towards completion of our Phase III studies and targeting our marketing phase,” he says. “Pluristem today holds major assets and I look forward to continuing to serve Pluristem as executive chairman and to work with Yaky and the team to generate value for these assets. I am delighted with this appointment and I am confident in Yaky’s capabilities to lead the company to become a global leader in the development, manufacture and marketing of Pluristem’s novel cell-based therapeutics.”